英文名称 |
中文名称 |
CAS号 |
操作 |
Nintedanib Ethanesulfonate Salt |
尼达尼布乙磺酸盐 |
656247-18-6 |
详细
|
Alectinib Hydrochloride |
艾乐替尼盐酸盐 |
1256589-74-8 |
详细
|
LDN-192960 |
3-[(2,7-二甲氧基吖啶-9-基)硫基]丙胺 |
184582-62-5 |
详细
|
Mirk-IN-1 |
1386979-55-0 |
1386979-55-0 |
详细
|
Orelabrutinib |
奥布替尼 |
1655504-04-3 |
详细
|
Pralsetinib |
BLU-667(拉西替尼) |
2097132-94-8 |
详细
|
LDN-192960 hydrochloride |
LDN-192960 HYDROCHLORIDE |
2309172-48-1 |
详细
|
Acrizanib |
化合物ACRIZANIB |
1229453-99-9 |
详细
|
Lanraplenib succinate |
Lanraplenib (succinate) |
1800047-00-0 |
详细
|
UNC2025 hydrochloride |
UNC2025 盐酸盐 |
2070015-17-5 |
详细
|
ENMD-2076 |
6-(4-甲基-1-哌嗪基)-N-(5-甲基-1H-吡唑-3-基)-2-[(1E)-2-苯乙烯基]-4-嘧啶胺 |
934353-76-1 |
详细
|
AZM475271 |
476159-98-5 |
476159-98-5 |
详细
|
Fostamatinib disodium hexahydrate |
福他替尼钠盐水合物 |
914295-16-2 |
详细
|
Cediranib maleate |
西地尼布马来酸盐 |
857036-77-2 |
详细
|
PRT-060318 |
PRT-060318 |
1194961-19-7 |
详细
|
JH-VIII-157-02 |
化合物 T15612 |
1639422-97-1 |
详细
|
SRI 31215 TFA |
SRI-31215 BIS-TFA SALT |
1832686-44-8 |
详细
|
NVP-BHG712 isomer |
NVP-BHG712 isomer |
2245892-85-5 |
详细
|
Tyrphostin AG1433 |
Tyrphostin AG1433 |
168835-90-3 |
详细
|
DCC-3014 |
DCC3014 |
1628606-05-2 |
详细
|
RET-IN-3 |
化合物 RET-IN-3 |
2414374-53-9 |
详细
|
Cabozantinib S-malate |
苹果酸卡博替尼 |
1140909-48-3 |
详细
|
Ningetinib Tosylate |
对甲苯磺酸宁格替尼 |
1394820-77-9 |
详细
|
JNJ-38877618 |
JNJ-38877618 |
943540-74-7 |
详细
|
TAS-115 mesylate |
TAS-115 MESYLATE |
1688673-09-7 |
详细
|
AZ-Dyrk1B-33 |
3-(2-Methyl-4-pyrimidinyl)-1-(phenylmethyl)-1H-pyrrolo[2,3-c]pyridine |
1679330-37-0 |
详细
|
Jaspamycin |
JASPAMYCIN |
22242-96-2 |
详细
|
FGFR1/DDR2 inhibitor 1 |
FGFR1/DDR2 inhibitor 1 |
2308497-58-5 |
详细
|
Nocodazole |
诺考达唑 |
31430-18-9 |
详细
|
Vorolanib |
VOROLANIB |
1013920-15-4 |
详细
|
AZD7507 |
CS-2850 |
1041852-85-0 |
详细
|
UNC2541 |
UNC2541 |
1612782-86-1 |
详细
|
Y15 |
1,2,4,5-苯四胺四盐酸盐 |
4506-66-5 |
详细
|
Pazopanib Hydrochloride |
盐酸帕唑帕尼 |
635702-64-6 |
详细
|
SU16f |
化合物 T16947 |
251356-45-3 |
详细
|
R406 |
6-[[5-氟-2-[(3,4,5-三甲氧基苯基)氨基]-4-嘧啶基]氨基]-2,2-二甲基-2H-吡啶并[3,2-B]-1,4-恶嗪-3(4H)-酮苯磺酸盐 |
841290-81-1 |
详细
|
AC710 |
N-[4-[[[[5-(叔丁基)-3-异恶唑基]氨基]羰基]氨基]苯基]-5-[(1-乙基-2,2,6,6-四甲基-4-哌啶基)氧基]-2-吡啶甲酰胺 |
1351522-04-7 |
详细
|
(Rac)-IBT6A |
1412418-47-3 |
1412418-47-3 |
详细
|
Brigatinib |
布格替尼 |
1197953-54-0 |
详细
|
ARQ 531 |
ARQ-531 |
2095393-15-8 |
详细
|
Vecabrutinib |
维卡布鲁替尼 |
1510829-06-7 |
详细
|
Remibrutinib |
LOU-064 |
1787294-07-8 |
详细
|
BT-13 |
BT-13 |
924537-98-4 |
详细
|
cFMS Receptor Inhibitor II |
CFMS RECEPTOR INHIBITOR II |
959860-85-6 |
详细
|
Bozitinib |
BOZITINIB (PLB-1001) |
1440964-89-5 |
详细
|
BAY-474 |
化合物BAY-474 |
1033767-86-0 |
详细
|
WRG-28 |
WRG-28 |
1913291-02-7 |
详细
|
BIIB068 |
BIIB068 |
1798787-27-5 |
详细
|
BO-264 |
BO-264 |
2408648-20-2 |
详细
|
Lyn-IN-1 |
巴非替尼 |
887650-05-7 |
详细
|
Fostamatinib |
福他替尼 |
901119-35-5 |
详细
|
Lck inhibitor 2 |
3-[[4-[(5-羟基-2-甲基苯基)氨基]-2-嘧啶基]氨基]苯甲酰胺 |
944795-06-6 |
详细
|
Infigratinib phosphate |
NVP BGJ398 磷酸盐 |
1310746-10-1 |
详细
|
CP-547632 hydrochloride |
CP-547632 (hydrochloride) |
252003-71-7 |
详细
|
MK-8033 hydrochloride |
3-(1-甲基-1H-吡唑-4-基)-5-氧代-N-(2-吡啶基甲基)-5H-苯并[4,5]环庚三烯并[1,2-B]吡啶-7-甲烷磺酰胺盐酸盐 |
1283000-43-0 |
详细
|
INDY |
INDY |
1169755-45-6 |
详细
|
SKLB4771 |
FLT3-IN-1 |
1370256-78-2 |
详细
|
Gilteritinib hemifumarate |
GILTERITINIB FUMARATE |
1254053-84-3 |
详细
|
S49076 |
CS-2684 |
1265965-22-7 |
详细
|
MAZ51 |
CS-2885 |
163655-37-6 |
详细
|
RU-301 |
RU-301 |
1110873-99-8 |
详细
|
PDGFRα kinase inhibitor 1 |
PDGFRα kinase inhibitor 1 |
2209053-93-8 |
详细
|
SPP-86 |
1-(1-Methylethyl)-3-(2-phenylethynyl)-1H-pyrazolo[3,4-d]pyrimidin-4-amine |
1357349-91-7 |
详细
|
BMS-509744 |
N-(5-((5-(4-乙酰基哌嗪-1-甲酰基)-4-甲氧基-2-甲基苯基)硫基)噻唑-2-基)-4-(((3,3-二甲基丁烷-2-基)氨基)甲基)苯甲酰胺 |
439575-02-7 |
详细
|
MK-8033 |
MK-8033 |
1001917-37-8 |
详细
|
PF-06465469 |
PF 06465469
Discontinued See A191400 |
1407966-77-1 |
详细
|
Dubermatinib |
TP-0903 |
1341200-45-0 |
详细
|
PRN1008 |
瑞扎布鲁替尼 |
1575596-29-0 |
详细
|
Taletrectinib |
DS-6051b |
1505515-69-4 |
详细
|
A-770041 |
A-770041 |
869748-10-7 |
详细
|
Lck Inhibitor |
6-(2,6-二甲基苯基)-2-[[4-(4-甲基-1-哌嗪基)苯基]氨基]-嘧啶并[5',4':5,6]嘧啶并[1,2-A]苯并咪唑-5(6H)-酮 |
847950-09-8 |
详细
|
PLX647 |
10MG |
873786-09-5 |
详细
|
Ibrutinib D5 |
伊布替尼布D5 |
1553977-17-5 |
详细
|
PRN694 |
1575818-46-0 |
1575818-46-0 |
详细
|
TL02-59 |
3-(6,7-dimethoxyquinazolin-4-yloxy)-N-(4-((4-ethylpiperazin-1-yl)methyl)-3-(trifluoromethyl)phenyl)-4-methylbenzamide |
1315330-17-6 |
详细
|
FN-1501 |
1429515-59-2 |
1429515-59-2 |
详细
|
AZD3229 Tosylate |
AZD3229 Tosylate |
2248003-71-4 |
详细
|
CLK-IN-T3 |
CLK inhibitor T3
(T3) |
2109805-56-1 |
详细
|
VEGFR-2-IN-6 |
帕唑帕尼杂质3 |
444731-47-9 |
详细
|
TAM-IN-2 |
TAM-IN-2 |
2135642-56-5 |
详细
|
AGL-2263 |
AG 2263 |
638213-98-6 |
详细
|
Syk-IN-1 |
1,2,4-Triazine-6-carboxamide, 3-[[(1R,2S)-2-aminocyclohexyl]amino]-5-(1H-indol-7-ylamino)- |
1491150-77-6 |
详细
|
CP-547632 |
3-[(4-溴-2,6-二氟苄基)氧基]-5-[3-[4-(吡咯烷-1-基)丁基]脲基]异噻唑-4-甲酰胺 |
252003-65-9 |
详细
|
Tivozanib |
替沃扎尼 |
475108-18-0 |
详细
|
DPH |
5-(3-(4-氟苯基)-1-苯基-1H-吡唑-4-基)咪唑烷-2,4-二酮 |
484049-04-9 |
详细
|
KB SRC 4 |
1-[3-[1-([1,1'-Biphenyl]-3-ylMethyl)-1H-1,2,3-triazol-5-yl]phenyl]-3-(4-chlorophenyl)-1H-pyrazolo[3,4-d]pyriMidin-4-aMine |
1380088-03-8 |
详细
|
Osteogenic Growth Peptide (10-14) |
OSTEOGENIC GROWTH PEPTIDE (10-14) |
105250-85-9 |
详细
|
trans-Pralsetinib |
cis-Pralsetinib hydrochloride (cis-BLU-667 hydrochloride) |
2097132-93-7 |
详细
|
Src Inhibitor 3 |
Src Inhibitor 3 |
2380027-49-4 |
详细
|
Hck-IN-1 |
Nef-IN-B9 |
1473404-51-1 |
详细
|
CA-4948 |
4-Oxazolecarboxamide, N-[5-[(3R)-3-hydroxy-1-pyrrolidinyl]-2-(4-morpholinyl)oxazolo[4,5-b]pyridin-6-yl]-2-(2-methyl-4-pyridinyl)- |
1801344-14-8 |
详细
|
RET V804M-IN-1 |
化合物RET V804M-IN-1 |
2414909-94-5 |
详细
|
I-OMe-Tyrphostin AG 538 |
I-OME-AG 538 |
1094048-77-7 |
详细
|
Pivanex |
(2,2-二甲基-1-氧代丙氧基)丁酸甲酯 |
122110-53-6 |
详细
|
Petunidin chloride |
矮牵牛素PT |
1429-30-7 |
详细
|
TIE-2/VEGFR-2 kinase-IN-1 |
6-(4-甲氧基苯基)呋喃并[2,3-D]嘧啶-4-胺 |
453590-24-4 |
详细
|
PF-04217903 methanesulfonate |
PF 04217903 MESYLATE |
956906-93-7 |
详细
|
3-Hydroxy Midostaurin |
CGP52421 |
179237-49-1 |
详细
|
Conteltinib |
CONTELTINIB (CT-707) |
1384860-29-0 |
详细
|
CH6953755 |
CH6953755 |
2055918-71-1 |
详细
|